Efficacy and Safety of Ferric Carboxymaltose Injection in Reducing Anemia in Patients Receiving Chemotherapy for Non-Myeloid Malignancies: A Phase 3, Placebo-Controlled Study (IRON CLAD)

医学 转铁蛋白饱和度 内科学 贫血 铁蛋白 安慰剂 化疗方案 化疗 外科 胃肠病学 缺铁 替代医学 病理
作者
Jeffrey A. Gilreath,Tamta Makharadze,Ralph V. Boccia,Anna Krupa,David H. Henry
出处
期刊:Blood [Elsevier BV]
卷期号:134 (Supplement_1): 3535-3535 被引量:3
标识
DOI:10.1182/blood-2019-132135
摘要

Background: In patients with chemotherapy-induced anemia (CIA), erythropoiesis stimulating agents (ESAs) are effective but are associated with potentially serious side effects, such as venous thromboembolism (VTE). The addition of iron to ESA therapy improves hematologic response, reduces risk of red cell transfusion, and is well tolerated (Mhaskar 2016). This raises the question as to whether intravenous (IV) iron alone accomplishes the same goals in patients with cancer (PwC). Several observational studies evaluating IV iron monotherapy in PwC receiving chemotherapy have demonstrated increases in hemoglobin (Hb) concentrations and/or reductions in transfusion rates, (Dangsuwan 2010, Kim 2007, Hedenus 2014) suggesting that IV iron monotherapy is a feasible treatment option for patients with CIA. However, prospective, randomized, placebo-controlled trial data evaluating the effect of IV iron in PwC and CIA has yet to be produced. This is the first randomized study to prospectively evaluate the safety and efficacy of an IV iron replacement therapy (ferric carboxymaltose (FCM; Injectafer), as monotherapy for patients with CIA. Design/Methods : This 18-week, double-blind, phase 3 study included adults >18 years of age with CIA receiving chemotherapy (≥4 weeks' treatment remaining) for a non-myeloid malignancy. Inclusion criteria included: (Hb) 8-11 g/dL, ferritin 100-800 ng/mL, and transferrin saturation (TSAT) ≤35%; an Eastern Cooperative Oncology Group Performance Status [ECOG PS] score of 0-2; and life expectancy ≥6 months. PwC were excluded if they received oral or IV iron, RBC transfusion, or ESAs within 4 weeks of screening; iron-containing multivitamins were permitted. Study patients were randomized 1:1 to receive IV FCM or IV placebo. FCM was administered as two 15-minute infusions each separated by 7 days, each at a dose of 15 mg/kg (maximum single dose: 750 mg [total dose ≤1500 mg] diluted in ≤250 mL saline). For blinding purposes, placebo was normal saline ≤250 mL, administered as covered 15-minute infusions. Patients were randomized 1:1 to receive FCM or placebo. The primary efficacy endpoint was percentage of patients with a decrease in Hb ≥0.5 g/dL from weeks 3 to 18; the secondary efficacy endpoint was change in Hb from baseline to end of treatment. Based on the assumption that 65% of patients in the placebo group and 42% of patients in the FCM group would not maintain baseline Hb concentrations, it was determined that 106 PwC were needed in each treatment group to provide 90% power to detect a statistically significant difference in the primary endpoint measured using a continuity-corrected 2-sided chi-squared test at a significance level of α=0.05. Results: The study randomized 244 PwC (n=122, both groups). The percentage of patients with a decrease in Hb ≥0.5 g/dL from weeks 3 to 18 was significantly lower with FCM versus placebo (35.3% vs 50.8%; odds ratio=0.51, P=0.01). Improvements from baseline Hb to end of treatment were not significantly different between FCM and placebo (1.04 vs 0.87 g/dL), but were greater with FCM in a subgroup of patients with baseline Hb <10 g/dL (P=0.01). The percentage of patients in the subgroup had an increase from baseline Hb of ≥1 g/dL (71% vs 54%, respectively; P=0.01) and a shorter median time to Hb increase of ≥1 g/dL (43 vs 85 days; P=0.001) versus placebo. The most common adverse events (AEs) were neutropenia (17% vs 12%), hypophosphatemia (16% vs 3%), and fatigue (15% vs 14%; FCM vs. placebo, respectively). VTE did not occur in any PwC in either arm. In general, FCM raised no safety signals and was well tolerated, with no notable difference between groups in the incidence of AEs other than hypophosphatemia. A decrease in serum phosphate (ie < 2.0 mg/dL) from Day 7 to Week 3 was seen in up to 38% of patients receiving FCM, however this did not produce any symptoms in affected patients. No differences were found between the FCM and placebo groups who received non-study interventions (22 [18%] vs 25 [21%], respectively), including those requiring blood transfusions (15 [13%] vs 14 [12%]). Conclusion: In this phase 3 trial of patients with CIA, Hb was maintained within ≥0.5 g/dL of baseline from weeks 3 to 18 in patients in 64.7% receiving FCM and 49.2% receiving placebo. Additionally, FCM maintained Hb for up to 18 weeks for the majority of PwC and CIA, and did not increase the risk for VTE. Disclosures Boccia: AMAG: Consultancy; AstraZeneca: Speakers Bureau; Amgen: Speakers Bureau; Celgene: Speakers Bureau; DSI: Speakers Bureau; Genentech: Speakers Bureau. Krupa:American Regent: Employment. OffLabel Disclosure: Unsure: This study discusses parenteral iron for chemotherapy-induced anemia. Currently, no IV iron product has a labeled indication for this specific patient population, however ferric carboxymaltose is indicated for adults who have intolerance to oral iron or have had unsatisfactory response to oral iron or adults who have non-dialysis dependent chronic kidney disease.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Augusterny完成签到 ,获得积分10
2秒前
秦磊发布了新的文献求助10
3秒前
跳脚的虾完成签到 ,获得积分10
4秒前
h41692011完成签到 ,获得积分10
4秒前
时势造英雄完成签到 ,获得积分10
5秒前
沟通亿心完成签到,获得积分10
5秒前
传奇3应助无心的雅旋采纳,获得10
5秒前
满意代萱完成签到 ,获得积分10
6秒前
dream完成签到 ,获得积分10
8秒前
芙瑞完成签到 ,获得积分10
8秒前
8秒前
xliiii完成签到,获得积分10
10秒前
纯爱完成签到,获得积分10
12秒前
阿米尔灿发布了新的文献求助10
14秒前
sdfdzhang完成签到 ,获得积分0
15秒前
16秒前
Zurlliant完成签到,获得积分10
17秒前
星辰大海应助舍弃采纳,获得10
18秒前
18秒前
19秒前
英俊的铭应助阿米尔灿采纳,获得10
19秒前
xyzlancet完成签到,获得积分10
19秒前
吴建文发布了新的文献求助10
20秒前
七月完成签到,获得积分10
20秒前
张张张xxx完成签到,获得积分10
20秒前
美女完成签到,获得积分10
23秒前
23秒前
卞卞发布了新的文献求助10
24秒前
无花果应助Hanguo采纳,获得10
25秒前
量子星尘发布了新的文献求助10
26秒前
huahua完成签到 ,获得积分10
26秒前
热心不凡完成签到,获得积分10
27秒前
zhang完成签到 ,获得积分10
27秒前
JUAN完成签到,获得积分10
27秒前
秦磊发布了新的文献求助10
27秒前
真实的采白完成签到 ,获得积分10
30秒前
cuddly完成签到 ,获得积分10
31秒前
时舒完成签到 ,获得积分10
31秒前
maxthon完成签到,获得积分10
31秒前
美女发布了新的文献求助10
31秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Social Research Methods (4th Edition) by Maggie Walter (2019) 2390
A new approach to the extrapolation of accelerated life test data 1000
北师大毕业论文 基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 390
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Robot-supported joining of reinforcement textiles with one-sided sewing heads 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4008786
求助须知:如何正确求助?哪些是违规求助? 3548464
关于积分的说明 11298867
捐赠科研通 3283080
什么是DOI,文献DOI怎么找? 1810290
邀请新用户注册赠送积分活动 886000
科研通“疑难数据库(出版商)”最低求助积分说明 811220